Market Overview

Benzinga's Top Initiations

Share:
Benzinga's Top Initiations
Related LJPC
Oppenheimer Is Excited About These 3 Biotech Stocks
La Jolla Pharmaceutical Company Announces Initiation of Phase 3 Clinical Trial of LJPC-501 in Catecholamine-Resistant Hypotension
Insider Wisdom And The New Medicine (Seeking Alpha)
Related DRII
Diamond Resorts International Commences Public Offering of 4.833M Shares
Credit Suisse 2015 Outlook On Gaming, Lodging & Leisure

Analysts at Jefferies initiated coverage on La Jolla Pharma (NASDAQ: LJPC) with a Buy rating. The target price for La Jolla Pharma is set to $25. La Jolla Pharma's shares closed at $9.40 on Friday.

Imperial Capital initiated coverage on shares of Diamond Resorts (NYSE: DRII) with a Outperform rating. The target price for Diamond Resorts is set to $34. Diamond Resorts' shares closed at $24.95 on Friday.

Latest Ratings for LJPC

DateFirmActionFromTo
Apr 2015OppenheimerInitiates Coverage onOutperform
Mar 2015Chardan CapitalReinstatesBuy
Aug 2014JefferiesInitiates Coverage onBuy

View More Analyst Ratings for LJPC
View the Latest Analyst Ratings

Posted-In: Top InitiationsInitiation Analyst Ratings

 

Related Articles (LJPC + DRII)

Around the Web, We're Loving...